Kathryn Flynn, PhD

Associate Professor

Locations

Department of Medicine
Division of Hematology and Oncology

Biography

Dr. Kathryn Flynn is an Associate Professor of Medicine at the Medical College of Wisconsin, Division of Hematology and Oncology. She is also the Senior Scientific Director for Patient-Reported Outcomes in the Center for International Blood and Marrow Transplant Research (CIBMTR). She was trained in sociology (BA, MS) and population health sciences (PhD).

Leadership Positions

Senior Scientific Director for Patient-Reported Outcomes Center for International Blood and Marrow Transplant Research

Research Interests

Dr. Flynn’s research focuses on the measure development and analysis of patient-reported outcomes as well as mixed methods approaches to understanding and improving patient-provider communication and patient decision making. She was a co-investigator in the PROMIS Network – NIH Roadmap initiative to standardize patient-reported outcomes measurement across diseases. She co-led development of the PROMIS Sexual Function and Satisfaction measure. She currently co-leads an NICHD R21 as well as a 14-site NCI-funded R01 examining clinical and patient-reported outcomes among patients with chronic myeloid leukemia who discontinue targeted therapies.

The association of pharmacy fill synchronization with breast cancer endocrine therapy adherence.

(Neuner JM, Fergestrom NM, Laud PW, Nattinger AB, Beyer KMM, Flynn KE, Pezzin LE.) Cancer. 2019 Nov 15;125(22):3960-3965.
Sexual Orientation and Patient-Provider Communication About Sexual Problems or Concerns Among US Adults.

(Flynn KE, Whicker D, Lin L, Cusatis R, Nyitray A, Weinfurt KP.) J Gen Intern Med. 2019 Nov;34(11):2505-2511.
Can 7 or 30-Day Recall Questions Capture Self-Reported Lower Urinary Tract Symptoms Accurately?

(Flynn KE, Mansfield SA, Smith AR, Gillespie BW, Bradley CS, Cella D, Clemens JQ, Helmuth ME, Lai HH, Kirkali Z, Talaty P, Weinfurt KP, LURN Study Group.) J Urol. 2019 10;202(4):770-778.
Incorporating patient-generated contextual data into care: Clinician perspectives using the Consolidated Framework for Implementation Science.

(Holt JM, Cusatis R, Asan O, Williams J, Nukuna S, Flynn KE, Moore J, Crotty BH.) Healthc (Amst). 2019 Aug 21:100369.
Reliability and validity of PROMIS® pediatric family relationships short form in children 8-17 years of age with chronic disease.

(Cox ED, Connolly JR, Palta M, Rajamanickam VP, Flynn KE.) Qual Life Res. 2019 Aug 10.
A new outcome measure for LUTS: Symptoms of Lower Urinary Tract Dysfunction Research Network Symptom Index-29 (LURN SI-29) questionnaire.

(Cella D, Smith AR, Griffith JW, Flynn KE, Bradley CS, Gillespie BW, Kirkali Z, Talaty P, Jelovsek JE, Helfand BT, Weinfurt KP, LURN Study Group.) Neurourol Urodyn. 2019 Aug;38(6):1751-1759.
A New Brief Clinical Assessment of Lower Urinary Symptoms for Women and Men: LURN SI-10.

(Cella D, Smith AR, Griffith JW, Kirkali Z, Flynn KE, Bradley CS, Jelovsek JE, Gillespie BW, Helfand BT, Talaty P, Weinfurt KP, and the LURN Study Group.) J Urol. 2019 Jul 31:101097JU0000000000000465.
Too much time? Time use and fertility-specific quality of life among men and women seeking specialty care for infertility.

(Cusatis R, Fergestrom N, Cooper A, Schoyer KD, Kruper A, Sandlow J, Strawn E, Flynn KE.) BMC Psychol. 2019 Jul 09;7(1):45.
Sexual Dysfunction and Reproductive Concerns in Young Men Diagnosed With Testicular Cancer: An Observational Study.

(Ljungman L, Eriksson LE, Flynn KE, Gorman JR, Ståhl O, Weinfurt K, Wiklander M, Lampic C, Wettergren L.) J Sex Med. 2019 Jul;16(7):1049-1059.
Parental Perceptions of Displayed Patient Data in a PICU: An Example of Unintentional Empowerment.

(Asan O, Scanlon MC, Crotty B, Holden RJ, Flynn KE.) Pediatr Crit Care Med. 2019 05;20(5):435-441.
Patients' perspectives on the definition of cure in chronic myeloid leukemia.

(Flynn KE, Mauro MJ, George G, Hinman A, Baim A, Kota V, Larson RA, Lipton JH, Thompson JE, Wadleigh M, Atallah E.) Leuk Res. 2019 May;80:40-42.
Baseline patient-reported outcomes in light-chain amyloidosis patients enrolled on an interventional clinical trial.

(D'Souza A, Hari P, Pasquini M, Jacobsen K, Flynn KE.) Amyloid. 2019;26(sup1):87-88.

Kathryn Flynn, PhD